移动医疗app在保障慢性病患者用药安全方面的有效性研究卡塔尔世界杯8强波胆分析系统评价与荟萃分析%周A，婷婷%王a，顾睿%贾思%谢a，李玲%赵a，清华%肖华%赵明%陈a，陆宇%+重庆医科大学第一附属医院护理部，重庆友义路1号，400001,86 13340224366;cyfyy_xieliling@163.com %K移动应用程序%K药物安全%K系统评价%K元分析%K移动健康%K移动健康%K健康应用%K依从性%K药品%K药物安全%K用药错误%K药物错误%K评价方法学%K搜索策略%K电子健康%K数字健康%K不良事件%K不良反应%D 2022 %7 22.11.2022 %9评价% jjmir移动健康Uhealth %G英语%X随着全球老龄化社会的快速增长，移动和健康数字市场得到了极大的扩展。无数移动医疗app (mmApps)在互联网市场上涌现，旨在帮助慢性病患者实现用药安全。目的:基于世界卫生组织提出的用药安全行动计划，我们旨在探讨mmApps在保障慢性病患者用药安全方面的有效性，包括mmApps是否能够提高药物不良事件(ADEs)的报告意愿，提高患者的用药依从性，减少用药错误。我们希望通过系统回顾和荟萃分析来验证我们的假设。方法:meta分析严格按照PRISMA(首选系统评价和meta分析报告项目)指南进行，文献检索自pubmed、Web Of Science、Embase、CINAHL、中国知识基础设施、万方和中国医学信息中心等7个数据库。发表时间以建库时间为限，至2022年4月30日。根据纳入和排除标准对研究进行筛选。 The data extracted included authors, years of publication, countries or regions, participants’ characteristics, intervention groups, and control groups, among others. Our quality assessment followed the guidelines of the Cochrane Handbook for Systematic Reviews of Interventions, Version 6.3. RevMan 5.2 software (Cochrane Collaboration) was used to analyze the statistical data, and a sensitivity analysis was performed to assess data stability. The degree of stability was calculated by using a different statistical method and excluding large-sample studies from the analysis. Results: We included 8 studies from 5 countries (China, the United States, France, Canada, and Spain) that were published from January 1, 2014, to December 31, 2021. The total number of participants was 1355, and we analyzed the characteristics of included studies, each app’s features, the risk of bias, and quality. The results showed that mmApps could increase ADE reporting willingness (relative risk [RR] 2.59, 95% CI 1.26-5.30; P=.009) and significantly improve medication adherence (RR 1.17, 95% CI 1.04-1.31; P=.007), but they had little effect on reducing medication errors (RR 1.54, 95% CI 0.33-7.29; P=.58). Conclusions: We analyzed the following three merits of mmApps, with regard to facilitating the willingness to report ADEs: mmApps facilitate more communication between patients and physicians, patients attach more importance to ADE reporting, and the processing of results is transparent. The use of mmApps improved medication adherence among patients with chronic diseases by conveying medical solutions, providing educational support, tracking medications, and allowing for remote consultations. Finally, we found 3 potential reasons for why our medication error results differed from those of other studies. Trial Registration: PROSPERO International Prospective Register of Systematic Reviews CRD42022322072; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=322072 %M 36413386 %R 10.2196/39819 %U https://mhealth.www.mybigtv.com/2022/11/e39819 %U https://doi.org/10.2196/39819 %U http://www.ncbi.nlm.nih.gov/pubmed/36413386